1GERLACH M,RELCHMANN H,RIEDERER P.Levodopa in the Treatment of Parkinson's Disease:Current Controversies[J].Mov Disord(S0885-3185),2004,19:997-1005.
2CALON F,RAJPT AH,HORNYKIEWICZ O,et al.Levodopa-induced Motor Complications Are Associated with Alterations of Glutamate Receptors in Parkinson's Disease[J].Neurobiol Dis(S0969-9961),2003,14(3):404-416.
3OH JD,CHASE TN.Glutamate2 Mediated Striatal Dysregulation and the Pathogenesis of Motor Response Complications in Parkinson's Disease[J].Amino Acids(S0939-4451),2002,23:133-139.
4GUIGONI C,AUBERT I,LI Q,et al.Pathogenesis of Levodopa-Induced Dyskinesia:Focus on D1 and D3 Dopamine Receptors[J].Parkinsonism Relat Disord(S1353-8020),2005,11:s25-s29.
5WESTIN JE,ANDERSSON M,LUNDBLAD M,et al.Persistent Changes in Striatal Gene Expression Induced by Long-term L-dopa treatment in a Rat Model of Parkinson's Disease[J].Eur J Neurosci(S0953-816X),2001,14:1171-1176.
6PALHAGENN S,HELNONEB EH,HAGGLUNG J,et al.Selegiline Delays the Onset of Disability in Denovo Parkinsonian Patients[J].Neurology(S0028-3878),1998,51:520-525.
7The Parkinson Study Group.Impact of Deprenyl and Tocopherol Treatment on Parkinson's Disease in DATATOP Patients Requiring Levodopa[J].Ann Neurol(S0364-5134),1996,39:29-36.
8MIYASAKI JM,MARTIN W,SUCHOWERSKY O,et al.Practice Parameter:Initiation of Treatment for Parkinson's Disease:An Evidence-based Review:Report of the Quality Standards Subcommittee of the American Academy of Neurology[J].Neurology(0028-3878),2002,58:11-17.
9PETZ K,HAGELL P,Odin P.Subcutaneous Apomorphine in Late Stage Parkinson's Disease:a Long Term Follow up[J].J Neurol Neurosurg Psychiatry(S0022-3050),1998,65:709-716.
10BARONTI F,MOURADIAN MM,DAVIS TL,et al.Continuous Lisuride Effects on Central Dopaminergic Mechanisms in Parkinson's disease[J].Ann Neurol(S0364-5134),1992,776-781.
